Combioxin develops disruptive life-saving solutions that revolutionize the treatment severe infections such as pneumonia, the most frequent and deadliest infectious disease. CAL02 has been ranked a “milestone” and “medical breakthrough”. CAL02 provides a totally new and eagerly awaited solution. This non-antibiotic drug is a universal toxin trap used on top of any antibiotic and regardless of resistance. CAL02 will transform standard of care and reduce cost of care for millions of patients.